Evicenter
MarkdownMedical informationP&T meetings

Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Section 2 of 6

Executive summary

13 evidence topics · 81 sources

Clinical benefits of Cretostimogene grenadenorepvec

Burden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Summary: definition and epidemiology

The 2026 European Association of Urology guidelines define BCG-unresponsive tumours as all BCG-refractory tumours and high-grade Ta/T1 recurrence within 6 months or carcinoma in situ (CIS) within 12 months of completion of adequate BCG exposure, where adequate BCG is at least five of six doses of an initial induction course plus at least two of six doses of a second induction course or two of three doses of maintenance therapy. FDA guidance also includes T1 high-grade disease at the first evaluation following induction BCG and states that patients with BCG-unresponsive NMIBC “are unlikely to benefit from further therapy with BCG”.

  • Bladder cancer in the United States: the American Cancer Society estimates 84,530 new cases and 17,870 deaths in 2026, with in situ disease included in the case estimate; SEER reports 17.9 new cases per 100,000 per year, a median age at diagnosis of 73, and an estimated 763,031 people living with bladder cancer in 2023. A second source reports a prevalence of 744,039 individuals in 2022.
  • Share diagnosed as NMIBC: 74% and approximately three-quarters in two 2026 articles, 73.1% in a SEER-Medicare analysis cited by a 2026 budget impact analysis of nadofaragene firadenovec, and approximately 70% in the 2020 ICER review.
  • BCG failure: three sources report that initial BCG fails in approximately 40% of patients over a 2-year span, that high-risk NMIBC recurs after adequate BCG in approximately 40%, and that more than 40% of patients with high-risk NMIBC do not respond to initial BCG.
  • The eligible-population estimates apply stage and BCG-response proportions to bladder cancer figures. The 2020 ICER review assumed approximately 38% BCG non-responders and, starting from a SEER prevalence of 712,614 people in 2017, estimated 70,135 eligible individuals, 51,180 (73%) with Ta and T1 disease and 18,956 (27%) with CIS. The 2026 budget impact analysis cites a SEER bladder cancer prevalence of 0.0634% and incidence of 0.0244% and SEER-Medicare proportions of 42.3% high-risk among NMIBC, 56.5% of high-risk NMIBC treated with BCG, and 30% of those unresponsive, and estimate that a health plan with one million lives has 5.5, 4.9, and 4.5 adults with high-risk BCG-unresponsive NMIBC with CIS ± Ta/T1 eligible for nadofaragene firadenovec in Years 1 to 3, or 33.2, 29.7, and 27.5 when Ta/T1-only disease is added.
  • Real-world classification: in a cohort of 26,876 participants with NMIBC, 3,134 of 5,271 participants (59.3%) with CIS-containing tumors and sufficient follow-up recurred within 24 months, of whom 530 (16.9%) were BCG unresponsive and 2,604 (83.1%) BCG exposed, and 24.9% (4,951 of 19,889) of participants across all risk groups received maintenance BCG. In a retrospective cohort at Moffitt Cancer Center (1988 to 2024), 470 of 1,076 participants with BCG-treated high-grade NMIBC were classifiable, of whom 225 (47.9%) were BCG-unresponsive. A 2026 article reports that a substantial proportion of patients cannot be classified because the exposure-based and time-dependent conditions of regulatory definitions are not met in routine practice.
Summary: natural history, survival, and treatment morbidity
  • Bladder cancer is the tenth leading cause of cancer death in the United States, with a death rate of 4.1 per 100,000 per year in SEER data. The American Cancer Society reports five-year relative survival of 79% overall and 98% for in situ disease.
  • In a SEER-Medicare analysis of 7,410 participants with high-risk bladder cancer, 2,897 (39.1%) had a recurrence without progression and 2,449 (33.0%) progressed, of whom 981 died of bladder cancer; 10-year recurrence, progression, and bladder cancer-related mortality rates were 74.3%, 33.3%, and 12.3%.
  • In one cohort, progression-free survival time was 18 months for 17 BCG-refractory participants and 52 months for 15 BCG-relapsing participants (P = 0.001); 8 (47%) and 3 (20%) had died. Among 85 participants with T1 recurrence treated initially with repeat transurethral resection and intravesical BCG, the 5-year cumulative incidence of progression to T2 disease was 71% and of death from disease 48%; in a cohort of 129 participants with recurrent T1, of whom 65 underwent immediate radical cystectomy, the corresponding figures were 28% and 31%.
  • Among adults with high-risk BCG-unresponsive NMIBC, 92.6% and 81.2% were alive at Years 2 and 3 in a SEER-Medicare analysis.
  • In a cohort of 578 participants with BCG-unresponsive NMIBC (28% upfront radical cystectomy, 72% bladder-sparing therapy; median follow-up 50 months), metastasis-free, cancer-specific, and overall survival did not differ significantly between groups. With bladder-sparing therapy, high-grade recurrence rates were 37% and 52% and progression to MIBC 7% and 13% at 12 and 24 months.
  • In a cohort of 570 participants previously treated with induction BCG (371 selected bladder-sparing therapy, 199 radical cystectomy), cancer-specific survival was 99% and 96%, and 12-month progression-free survival was 92% and 73%, respectively, with 22% of participants undergoing radical cystectomy having pathology demonstrating MIBC. Within 12 months, 27 (8.1%) participants in the bladder-sparing arm underwent radical cystectomy. Adverse events occurred in 62% after radical cystectomy and 38% with bladder-sparing therapy; after radical cystectomy, 57 (30%) participants were readmitted and five (2.5%) died within 90 days.
  • Long-term morbidity of urinary diversion: in one series, 643 participants (60.8%) had 1,453 complications attributable to the diversion, and in a cohort of 563 participants who underwent cystectomy with urinary diversion, mean glomerular filtration rate losses at 5 years were 17% and 14% of baseline in the two diversion groups.
Summary: humanistic and economic burden
  • Health-related quality of life: in the same cohort of 570 participants, the primary outcome, EORTC QLQ-C30 physical function at 12 months, did not differ between bladder-sparing therapy and radical cystectomy (mean 85.4 and 86.2; P = .22), after being worse with radical cystectomy at 3 months. At 12 months, emotional function, cognitive function, global health, anxiety, and depression were better with radical cystectomy, and bowel and sexual summary scores were worse. In another study, NMIBC survivors had lower quality of life than the general population, especially in fatigue, physical and role functioning, and mental health. Across 17 studies totaling 20,045 participants, withdrawal rates reached up to 90% in intensive instillation schedules.
  • Utilities: in time trade-off interviews with 202 members of the UK general public, mean utilities were 0.781 for no high-grade recurrence, 0.586 for high-grade recurrence, 0.288 for the first year after cystectomy, 0.572 for more than 1 year after cystectomy, and 0.283 for metastatic disease.
  • Preferences and treatment burden: among 206 respondents with self-reported NMIBC in a discrete-choice experiment survey, most (>70%) preferred bladder-sparing treatments over radical cystectomy except when comparing repeated BCG with radical cystectomy. Among 233 respondents to a survey on intravesical therapy, 61 (26%) reported that receiving bladder instillations adversely affected their regular daily activities, 55% (126/231) traveled more than 30 minutes to treatment, 56% (128/232) brought caregivers, and 36% (82/230) missed work.
  • Costs after BCG: among 986 participants aged 65 years or older with high-grade NMIBC who received adequate BCG induction (SEER-Medicare, diagnosed 2008 to 2015), 257 (26.1%) progressed; mean total annualized costs per patient after BCG were $39,102 overall, $65,668 with progression, and $29,780 without. Among 412 participants with high-risk NMIBC treated with BCG in Veterans Affairs centers, median costs (2019 USD) were $29,459 at 1 year, $55,267 at 2 years, and $117,361 at 5 years, and median 5-year costs were $232,729 with progressive disease and $94,879 without.
  • Costs of radical cystectomy and progression: median per-patient costs for 839 participants undergoing radical cystectomy were $70,671 at 90 days and $211,671 by 5 years. A Markov model estimated 5-year cumulative costs of $366,143 for high-risk NMIBC, with progression to muscle-invasive disease contributing 92% of the cost. Population changes are projected to increase bladder cancer care costs by 45% from 2015 through 2030, against an average of 39% across cancer sites.
  • Financial burden on patients and families: in the cohort of 570 participants, those in the bladder-sparing arm reported higher financial toxicity at 12 months than those in the radical cystectomy arm. Among 100 surveyed participants with NMIBC, the median COST score was 23, 61% reported at least mild financial toxicity, and 21% moderate financial toxicity. One article reports a roughly 60% retirement rate after bladder cancer diagnosis, a 22% unemployment rate among previously full-time workers, and surveillance accounting for more than half of the costs of the disease.

Cretostimogene grenadenorepvec efficacy and safety

Summary: BOND-003 Cohort C, cretostimogene monotherapy in CIS-containing disease
  • Regulatory stage: cretostimogene is investigational, and the company states that its safety and efficacy have not been established by the FDA or any other health authority. The company initiated a rolling Biologics License Application (BLA) for cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC in the fourth quarter of 2025 according to the Form 10-K and in November 2025 according to a Kissei release. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the initial BLA would be broadened to include high-grade papillary-only disease, with completion anticipated in March 2027.
  • Design and participants: Cohort C is a single-arm, open-label, phase 3 study in participants with BCG-unresponsive CIS with or without concomitant high-grade Ta/T1 papillary disease, done in 41 centres in North America, Asia, and Australia. Between October 9, 2020, and August 3, 2023, 165 participants were assessed for eligibility, 115 were enrolled, and 112 received cretostimogene as a 6-week induction followed by maintenance, with re-induction permitted for persistent disease at 3 months; 110 participants were efficacy evaluable. Responses were centrally confirmed, and bladder mapping at month 12 was mandatory.
  • Primary endpoint: complete response at any time was observed in 83 of 110 participants (75.5%; 95% CI 66.3% to 83.2%) as of the June 23, 2025 data cutoff, at a median follow-up of 25.8 months (IQR 22.1 to 33.1). The company states that the cohort “met its primary endpoint with statistical significance”.
  • Landmark complete response: 46.4% at 12 months (51 of 110; 95% CI 36.9 to 56.1 on the SUO 2025 poster and 36.8 to 56.1 in a 2026 presentation) and 41.8% at 24 months (46 of 110; 95% CI 32.5 to 51.6).
  • Durability: median duration of response was 27.9 months (95% CI 14.3 to not estimable) and ongoing. The estimated duration of response at 12 and 24 months was 64.2% (95% CI 52.2 to 73.8) and 60.1% (95% CI 48.2 to 70.0) in a 2026 presentation and the company's 2026 publication release; the company's September 2025 release and one passage of the Form 10-K give 64.1% and 58.3% for the same cutoff, the values a 2025 presentation reported at the March 14, 2025 cutoff. Of participants re-induced, 50.0% converted to complete response.
  • Progression and cystectomy: 106 of 110 participants (96.4%) were free from progression to T2 or higher disease in a 2026 presentation; the company's 2026 publication release states 96.6% at 48 and 96 weeks and that 3.4% progressed. Kaplan-Meier cystectomy-free survival was 89.2% (95% CI 81.3 to 93.9) at 12 months and 81.3% (95% CI 71.8 to 87.8) at 24 months in one presentation, and a 2026 translational presentation gives 85% at 24 months. Eighteen participants underwent radical cystectomy after recurrence (12) or progression (6).
  • Safety (112 participants): 71 (63.4%) had at least one treatment-related adverse event (TRAE), most often bladder spasm (28; 25.0%), pollakiuria (25; 22.3%), urgency (23; 20.5%), dysuria (21; 18.8%), and hematuria (15; 13.4%). No grade 3 or higher TRAEs, treatment-related discontinuations, or treatment-related deaths occurred, and the median time to TRAE resolution was 1 day. Two participants (1.8%) had serious grade 2 TRAEs: non-infective cystitis and, depending on the source, urinary bladder haemorrhage (publication) or clot retention (2026 presentation and Form 10-K). No health-related quality of life results were identified.
Summary: BOND-003 Cohort P, cretostimogene monotherapy in papillary-only disease
  • Design and role: Cohort P is a single-arm, open-label cohort of BOND-003 in participants with BCG-unresponsive high-grade Ta/T1 papillary disease without CIS, with a registry target of up to 75 participants. The Form 10-K describes it as “Phase 3” and as “an exploratory study”, and the 2026 investor presentation as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”; in its PIVOT-006 topline release the company stated that the initial BLA would be broadened to include high-grade papillary-only disease. Enrollment began in March 2024 according to a 2025 congress presentation; the Form 10-K and Form 10-Q state that the cohort was initiated in April 2024.
  • Participants: at the September 1, 2025 data cutoff, 56 participants were in the safety dataset and 51 were efficacy evaluable at a median follow-up of 6.0 months; the 2026 investor presentation lists an efficacy population of “N=54”. Tumor stage at entry was 33 high-grade Ta and 23 high-grade T1 in the SUO 2025 presentation and 37 and 19 in a 2026 poster that also reports 11 participants re-induced, against 8 re-induced at 3 months in another 2026 poster. Of participants, 96.4% were enrolled in the US.
  • Primary endpoint: the registry and congress presentations name high-grade event-free survival (HG-EFS); one passage of the Form 10-K names “overall event-free survival”. Kaplan-Meier estimates of HG-EFS were 95.7% (95% CI 83.8 to 98.9) at 3 months, 84.6% (95% CI 68.6 to 92.9) at 6 months, and 80.4% (95% CI 62.3 to 90.4) at 9 months, with 5 censored participants pending efficacy assessment; the SUO 2025 slide labels the same estimates high-grade recurrence-free survival. The 12-month estimate was “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
  • Progression and cystectomy: no participant underwent radical cystectomy or progressed to muscle-invasive disease, and 1 participant progressed to metastatic urothelial carcinoma despite a clinical complete response in the bladder.
  • Safety (56 participants, September 1, 2025 cutoff): 40 (71.4%) had at least one TRAE, most often bladder spasm (26; 46.4%), dysuria (22; 39.3%), pollakiuria (14; 25.0%), and urgency (11; 19.6%). No grade 3 or higher TRAEs, serious TRAEs, deaths, treatment-related discontinuations, or dose delays or missed doses due to TRAEs were reported. The Form 10-K also lists hematuria among the most common TRAEs (10% or more).
Summary: CORE-001, cretostimogene with pembrolizumab
  • Design and participants: CORE-001 is an open-label, single-group phase 2 study of intravesical cretostimogene with intravenous pembrolizumab in participants with BCG-unresponsive NMIBC with CIS with or without Ta/T1 papillary disease, with Merck Sharp & Dohme LLC as collaborator. It started on December 8, 2020, at 19 locations. Thirty-five participants were treated, 30 (85.7%) in the USA and 5 (14.3%) in Korea. Cretostimogene was given weekly for 6 weeks, then as three weekly maintenance instillations at months 3, 6, 9, 12, and 18 in participants maintaining complete response, and pembrolizumab for up to 24 months.
  • Primary endpoint: complete response at 12 months, assessed with mandatory bladder mapping biopsies, was 57.1% (20 of 35; 95% CI 40.7% to 73.5%) in the publication, meeting the primary endpoint. The company reports the same 20 of 35 with a 95% CI of 40% to 73% (February 5, 2024 cutoff, press release) and 39.5% to 73.2% (May 17, 2024 cutoff, Form 10-K).
  • Other efficacy outcomes: 29 of 35 participants (82.9%; 95% CI 70.4% to 95.3%) had a complete response at 3 months. At a median follow-up of 26.5 months, median duration of response was not reached (95% CI 15.7 to not reached). Complete response at 24 months was 51.4% (18 of 35; 95% CI 34.9% to 68.0%) in the publication and 54% (19 of 35; 95% CI 37% to 71%) at the May 17, 2024 cutoff in the company press release (54.3%, 95% CI 36.9% to 70.8%, in the Form 10-K). No participant progressed to muscle-invasive bladder cancer, and the company reports cystectomy-free survival of 80% at 24 months.
  • Safety (35 participants): 32 (91.4%) had at least one study drug-related adverse effect and 5 (14.3%) had grade 3 treatment-related adverse effects; the most common were bladder spasm (17; 48.6%), fatigue (13; 37.1%), dysuria (9; 25.7%), and pollakiuria (9; 25.7%). The publication table states that there were no grade 3 to 5 cretostimogene-related adverse effects; an author correction removed abstract statements attributing immune-related adverse effects exclusively to pembrolizumab and states that attribution was “assessed by the treating physicians”.
Summary: BOND-002, cretostimogene monotherapy after BCG failure
  • Design and participants: BOND-002 was an open-label, single-arm, phase 2 study of CG0070 in participants with high-grade NMIBC who had failed BCG and refused cystectomy, started on June 2, 2015, at 17 locations. The registry lists 66 participants enrolled; the Form 10-K reports 65 (46 with CIS with or without Ta/T1 disease and 19 with Ta/T1 disease) and describes the population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. The registered primary endpoint is the proportion of participants with a durable complete response lasting 12 months or longer and assessed at 18 months; no result for it was identified.
  • Efficacy: at the April 2017 interim analysis of 45 participants with evaluable 6-month follow-up, complete response at 6 months was 47% (95% CI 32% to 62%): 58% (37% to 78%) for pure CIS, 50% (33% to 67%) for CIS with or without Ta/T1, and 33% (8% to 70%) for pure Ta/T1. The Form 10-K reports complete response at any time in 40 participants (61.5%), with median duration of response not reached after 18 months, and in 30 of 46 participants (65.2%; 95% CI 49.7% to 78.2%) with CIS-containing disease; the 2024 prospectus gives 65% (95% CI 50% to 78%) for the same 30 of 46 and reports 44% and 28% of patients with complete response at 6 and 12 months.
  • Safety: at 6 months the most common TRAEs were bladder spasms (36%), hematuria (28%), dysuria (25%), and urgency (22%), with flu-like symptoms (12%) and fatigue (6%). Grade 3 TRAEs were dysuria (3%) and hypotension (1.5%), with no grade 4 or 5 TRAEs, and the Form 10-K reports eight serious adverse events determined not related to cretostimogene.
Summary: V-0046, phase 1 dose escalation
  • Design and participants: V-0046 was a non-randomized, open-label, phase 1 dose-escalation study of intravesical CG0070 in bladder cancer after BCG failure, with a registered primary endpoint of the maximum tolerated or maximum feasible dose. Thirty-five participants received single or multiple (every 28 days × 3 or weekly × 6) infusions at 1 of 4 dose levels, from 1 × 10^12 to 3 × 10^13 viral particles. A maximum tolerated dose was not reached.
  • Efficacy: the 2012 publication reports a complete response rate of 48.6% across cohorts with a median duration of 10.4 months, and 63.6% (14 of 22) in the multidose cohorts. A 2010 congress report gives a complete response rate of 46% for all participants. A 2023 company presentation gives complete response at 3 months in 16 of 35 participants (46%), 13 of 22 (59%) on multi-dose schedules, and 7 of 9 (78%) on the weekly × 6 schedule, with a median duration of 8.4 months.
  • Safety: grade 1 to 2 bladder toxicities were the most common adverse events. The 2010 congress report states that no serious adverse events and one dose-limiting toxicity (grade 3 lymphopenia) were reported, and that flu-like illness occurred in 10% to 20% of participants.
Summary: safety across studies
  • Monotherapy in BOND-003: TRAEs occurred in 71 of 112 participants (63.4%) in BOND-003 Cohort C (June 23, 2025 cutoff) and 40 of 56 (71.4%) in Cohort P (September 1, 2025 cutoff), with no grade 3 or higher TRAEs and no treatment-related discontinuations in either cohort. Serious TRAEs occurred in 2 participants (1.8%, both grade 2) in Cohort C and none in Cohort P.
  • Most frequent TRAEs: bladder spasm occurred in 25.0% of Cohort C, 46.4% of Cohort P, and 36% of the BOND-002 interim population; dysuria in 18.8%, 39.3%, and 25%; and urgency in 20.5%, 19.6%, and 22%, respectively. In Cohort C the median time to TRAE resolution was 1 day.
  • Earlier monotherapy studies: BOND-002 reported grade 3 dysuria (3%) and hypotension (1.5%) and no grade 4 or 5 TRAEs; V-0046 reported one dose-limiting grade 3 lymphopenia, did not reach a maximum tolerated dose, and reported flu-like illness in 10% to 20% of participants (12% with flu-like symptoms in BOND-002).
  • Combination with pembrolizumab: in CORE-001, 32 of 35 participants (91.4%) had a study drug-related adverse effect and 5 (14.3%) had a grade 3 treatment-related adverse effect, with no grade 3 to 5 adverse effects attributed to cretostimogene.
  • BOND (NCT01438112), registered as an open-label, randomized phase 2/3 study, enrolled 22 participants and lists “Change in study design” as its reason for stopping; no efficacy or safety results for it were identified.

Budget impact of Cretostimogene grenadenorepvec

Summary: development status, price, and eligible population

CG Oncology initiated a rolling BLA for cretostimogene grenadenorepvec in BCG-unresponsive high-risk NMIBC in the fourth quarter of 2025. After FDA feedback, it plans to broaden the initial submission, which was focused on CIS with or without papillary tumors, to include high-grade papillary-only disease, and it expects to complete the submission “before the end of March 2027”. The company states that it has no products approved for sale. No price has been announced, and no budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found. The company’s Form 10-K states that “pricing of existing drugs may limit the amount we will be able to charge for our products”. A 2026 published budget impact analysis of nadofaragene firadenovec describes cretostimogene as “under investigation in ongoing trials for similar indications”.

CG Oncology estimates, from internal research derived from SEER data, secondary claims data analytics, and management assumptions, that BCG-unresponsive NMIBC “may represent up to 25,000 addressable patients”, and that high-risk and intermediate-risk NMIBC together potentially represent up to 150,000 addressable patients in the United States. SEER estimates 84,530 new cases of bladder cancer in 2026 and 763,031 people living with bladder cancer in the United States in 2023. In that budget impact analysis, in a hypothetical plan with one million lives, the number of adults with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1 eligible for nadofaragene firadenovec was 5.5 in Year 1, 4.9 in Year 2, and 4.5 in Year 3; adding Ta/T1-only disease gave 33.2, 29.7, and 27.5, and counting incident cases only gave 2.1 in each year. That model applied 56.5% BCG treatment among patients with high-risk NMIBC and 30% BCG unresponsiveness among those treated. The ICER review assumed that approximately 38% of patients would be BCG non-responders and, applying its proportions to a prevalent population of 712,614, estimated 70,135 eligible individuals, 51,180 (73%) with Ta and T1 disease and 18,956 (27%) with CIS.

Summary: comparator prices, Medicare payment limits, and dosing

Published wholesale acquisition costs of comparators are $62,740.70 for a box of nadofaragene firadenovec (Adstiladrin, “4 vials x 20 ml”), accurate as of October 2, 2026; $35,800.00 per 400 mcg/0.4 mL vial of nogapendekin alfa inbakicept (Anktiva), as of January 1, 2025; and $12,517.44 per pembrolizumab (Keytruda) dose given every 3 weeks or $25,034.88 per dose given every 6 weeks, current as of September 2026. No wholesale acquisition cost was found for the gemcitabine intravesical system (Inlexzo).

Medicare Part B payment limits effective October 1 through December 31, 2026, based on second-quarter 2026 ASP data, are $65,200.563 per therapeutic dose of nadofaragene firadenovec (J9029), $94.139 per 1 mcg of nogapendekin alfa inbakicept (J9028), $73,054.053 per 225 mg gemcitabine intravesical system (J9183), $62.253 per 1 mg of pembrolizumab (J9271), $3.532 per 1 mg of BCG live intravesical (J9030), $1,230.664 per 200 mg of valrubicin (J9357), $2.734 per 200 mg of gemcitabine (J9201), $0.471 per 1 mg of docetaxel (J9171), and $34.838 per 5 mg of mitomycin (J9280), each with 20% coinsurance.

The Form 10-K describes cretostimogene induction as six weekly doses; patients with a CR at month three receive three weekly doses every three months for the first 12 months and every six months for the next 24 months, and patients without a CR may receive a second six-week induction course at month 3. Nadofaragene firadenovec is instilled once every three months. Nogapendekin alfa inbakicept is given at 400 mcg with BCG once a week for 6 weeks, then once a week for 3 weeks at months 4, 7, 10, 13, and 19 (15 doses in total). Pembrolizumab is given for up to 24 months, at 200 mg every 3 weeks in the trial its label describes. The gemcitabine intravesical system (225 mg) is inserted once every 3 weeks for up to 6 months (8 doses), then once every 12 weeks for up to 18 months (6 doses).

Summary: published budget impact and cost-effectiveness analyses of comparators

The 2026 budget impact analysis, funded by Ferring Pharmaceuticals, estimated the budget impact of nadofaragene firadenovec from the perspective of a US third-party payer, in a hypothetical plan with one million covered lives over a 3-year horizon, in 2024 US dollars, with a unit cost of $60,000.00 per instillation and projected market shares of 2%, 6%, and 18% in Years 1 to 3 from Ferring market research. The base-case budget impact was $11,960, $35,452, and $101,099 in Years 1, 2, and 3, or $0.0010, $0.0030, and $0.0084 per member per month. Including papillary-only disease gave $0.0064 to $0.0548 per member per month over Years 1 to 3, and results were most influenced by uptake rate, drug cost, and target population size. The authors state that the market share estimate “should be interpreted as exploratory rather than predictive”. The ICER review set the price of nadofaragene firadenovec, which was not available at the time, equal to the annual price of pembrolizumab ($164,337). At that placeholder price, the potential budget impact was an additional cost of approximately $128,000 per patient in year one and cumulative costs of approximately $98,000 per patient by year five, and approximately 52% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of $819 million.

The ICER review estimated, against a hypothetical comparator with a 0% CR at 3 months, $151,000 per QALY gained for nadofaragene firadenovec, $114,000 for pembrolizumab, and $382,000 for oportuzumab monatox, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec; the review describes its base case as “the most optimistic scenario”. The report was updated on January 15, 2021, to correct a data entry error affecting nadofaragene firadenovec results in the Ta/T1 population. A 2026 Markov model over 5 years from the US Medicare perspective at a willingness-to-pay threshold of $100,000 per QALY, found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy; nadofaragene became cost-effective with a 21% reduction in 3-month cost, and nogapendekin alfa inbakicept plus BCG would require a 67% reduction. A 2026 analysis funded by Johnson & Johnson built a 15-month cost-per-responder model from a Medicare payer perspective: the proportion achieving and sustaining CR for 12 months or longer was 43.5% for TAR-200, 18.8% for pembrolizumab, 21.9% for nadofaragene firadenovec, 26.8% for nogapendekin alfa inbakicept plus BCG (36.6% with reinduction), and 10.1% for valrubicin, at a total cost per patient of $823,824, $485,781, $504,487, $731,075, and $347,861, respectively.

Other analyses of pembrolizumab report different results. One analysis found pembrolizumab not cost-effective for BCG-unresponsive CIS relative to radical cystectomy or salvage intravesical chemotherapy, and another estimated $168,000 per QALY gained for pembrolizumab in CIS and stated that a 5.4% price reduction would make it cost-effective; The second analysis also estimated $263,000 and $145,000 per QALY gained for nadofaragene firadenovec in CIS and non-CIS populations at a placeholder price 10% above that of pembrolizumab. A further analysis, against radical cystectomy at a willingness-to-pay threshold of $100,000, estimated $10,014 per QALY for nadofaragene firadenovec and $44,602 per QALY for nogapendekin alfa inbakicept, and found that pembrolizumab dominated. At a willingness-to-pay threshold below €50,000 per QALY, another analysis found that pembrolizumab would be cost-effective only with a price reduction of at least 70%. ImmunityBio reported preliminary results of a health economic analysis, based on an indirect treatment comparison, with savings per complete responder of $313,775 at Year 1 and $282,013 at Year 2 for nogapendekin alfa inbakicept plus BCG compared with TAR-200.

Conclusions

Summary

Cretostimogene grenadenorepvec is investigational; its safety and efficacy “have not been established by the FDA or any other health authority”. The rolling BLA, initiated in November 2025, is to include both CIS and high-grade papillary-only disease after FDA feedback, with completion anticipated in March 2027. No price has been announced.

The efficacy evidence comes from single-arm studies. In the phase 3 BOND-003 Cohort C, 83 of 110 participants (75.5%) had a complete response at any time as of the June 23, 2025 cutoff; landmark complete response was 46.4% at 12 months and 41.8% at 24 months, and median duration of response was 27.9 months. In Cohort P (papillary-only disease), estimated 9-month HG-EFS was 80.4% in 51 efficacy evaluable participants as of the September 1, 2025 cutoff. In the phase 2 CORE-001 trial with pembrolizumab, complete response at 12 months was 57.1% (20 of 35). Treatment-related adverse events occurred in 71 of 112 participants (63.4%) in Cohort C and 40 (71.4%) in Cohort P, none of grade 3 or higher.

The EAU guideline describes radical cystectomy as “the standard and preferred option”. Nadofaragene firadenovec, pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each evaluated in single-arm trials, with labeled complete response rates of 51%, 41%, 62%, and 82%, respectively.

No randomized comparison of cretostimogene with any of these options and no health-related quality of life results were identified. Only the abstract of the peer-reviewed Cohort C report could be quoted, and the prespecified statistical threshold was not found. For the same cutoff, company documents report 12- and 24-month duration of response of 64.2% and 60.1% in a 2026 presentation and 64.1% and 58.3% in the Form 10-K, and describe Cohort P as “an exploratory study” in the Form 10-K and as “currently not intended for regulatory approval” in a 2026 investor presentation.